Biogen

In News

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion - WSJ

WSJ - Mar 31, 2026

Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media

Medical Marketing and Media - Apr 03, 2026

Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times

Ophthalmology Times - Apr 03, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

Biogen - Mar 31, 2026

Biogen to acquire immunology biotech Apellis for $5.6 billion - statnews.com

statnews.com - Mar 31, 2026

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - Biogen

Biogen - Mar 28, 2026

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen

Biogen - Mar 30, 2026

Biogen, with $5.6B Apellis buy, builds out immunology offerings - BioPharma Dive

BioPharma Dive - Mar 31, 2026

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy - BioSpace

BioSpace - Mar 31, 2026

Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily

Investor's Business Daily - Mar 31, 2026

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance

Yahoo Finance - Apr 03, 2026

Biogen gets FDA approval for higher dose of genetic disorder drug - Reuters

Reuters - Mar 30, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment